IgA肾病的降脂治疗

Lipid-Lowering Treatment for IgA Nephropathy

摘要: 目的：IgA肾病(IgA Nephropathy, IgAN)是最常见的原发性肾小球疾病，临床表现为肾炎综合征或肾病综合征，多呈慢性进展的疾病过程，是我国导致终末期肾脏疾病的首要原因。目前IgA肾病相关的临床研究主要集中在蛋白尿、高尿酸血症、高血糖、高血压等与疾病进展之间的关系，高脂血症对IgA肾病的预后及其治疗的研究报道较少，据Cai GY等报道：约20%的肾病患者10年后进展为慢性肾脏病(Chronic Kidney Disease, CKD)。CKD常常合并心血管疾病(Cardiovascular, CVD)，而高脂血症又是CVD的重要进展因素，因此应予重视。本文就IgAN高脂血症发病机制及治疗进展进行综述。

Abstract: Objective: IgA nephropathy (IgAN) is the most common primary glomerular disease, presenting clinically as either nephritic syndrome or nephrotic syndrome. It is a chronic progressive disease and the leading cause of end-stage renal disease in China. Currently, clinical research on IgAN mainly focuses on the relationship between proteinuria, hyperuricemia, hyperglycemia, hyperten-sion, and disease progression. There are fewer studies reporting on the prognosis and treatment of IgAN related to dyslipidemia. According to Cai GY et al., approximately 20% of kidney disease pa-tients progress to chronic kidney disease (CKD) after 10 years. CKD often coexists with cardiovascu-lar diseases (CVD), where dyslipidemia plays a significant role in its progression. Therefore, it should be given due attention. This article provides an overview of the pathogenesis and treatment advances in dyslipidemia associated with IgAN.